| 2.36 0 (0%) | 11-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
NeuroBo Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm committed to advancing treatments for a spectrum of challenging conditions, encompassing neurodegenerative disorders, infectious diseases, and cardiometabolic ailments. The company's diverse pipeline includes several investigational therapies: ANA001, an orally administered formulation of niclosamide, is currently progressing through Phase 2/3 clinical trials to treat individuals with moderate coronavirus disease (COVID-19). NB-01 is being developed to alleviate the discomfort associated with painful diabetic neuropathy. NB-02 targets the management of cognitive decline symptoms and seeks to alter the course of neurodegenerative conditions specifically linked to the malfunction of tau protein. Gemcabene is also part of their portfolio, under investigation for its potential in acute COVID-19 indications. NeuroBo Pharmaceuticals, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Thu, 24 Apr 2025
NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis - Stock Titan
Mon, 13 Jan 2025
2024 Initations - Zacks Small Cap Research
Sat, 30 Nov 2024
MetaVia (Nasdaq:MTVA) - Stock Analysis - Simply Wall St
Mon, 01 Jul 2024
NRBO: DA-1726 Shows Superiority to Survodutide in Pre-Clinical Models… - Zacks Investment Research
Wed, 06 Mar 2024
Mellody Hobson on why more firms should embrace co-CEOs like Ariel Investments: 'You have a shoulder to lean on' - Fortune
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|